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Introduction: Advanced gastric carcinoma often decreases quality of life because of upper gastrointestinal tract
stenosis. Self-expandable metal stents have been thought to be an effective, minimally invasive treatment for
stenosis. However, the effectiveness of self-expandable metal stent placement for carcinomatous stenosis of the
gastric body and antrum has not been clarified, and there have been few reports of such cases.
Case presentation: A 74-year-old Japanese woman developed stenosis of the gastric body and antrum caused by
advanced gastric cancer during first-line chemotherapy. She developed weight loss and poor nutrition due to
inadequate intake. Self-expandable metal stent placement for stenosis of the gastric body and antrum ameliorated
her symptoms rapidly and improved her general condition and quality of life. Eight days after self-expandable metal
stent placement, second-line chemotherapy could be administered safely. Oral intake and nutritional status were
maintained for 117 days after self-expandable metal stent placement, and she died of gastric cancer 176 days after
self-expandable metal stent placement and initiation of second-line chemotherapy.
Conclusions: Self-expandable metal stent placement for carcinomatous stenosis in the gastric body and antrum
could be an effective therapeutic strategy for patients with inadequate oral uptake. It may provide rapid
improvement of the patient’s general condition and oral intake with minimal complications, comparatively
long-term symptom relief, and a survival benefit by allowing second-line chemotherapy.Introduction
Advanced gastric carcinoma is a serious disease that
not only has a poor prognosis but also decreases quality
of life (QOL) because of upper gastrointestinal tract
stenosis. Bypass surgery has been conventionally per-
formed to relieve this condition and improve the QOL
of these patients [1]. Although palliative gastrostomy and
ileostomy and gastric tube insertion have been performed
for patients in poor general condition previously [2,3]
(many of whom could not undergo bypass surgery), self-
expandable metal stents (SEMS) have been recognized* Correspondence: e-baba@intmed1.med.kyushu-u.ac.jp
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reproduction in any medium, provided the oras an effective, minimally invasive treatment in recent
years [4-6]. SEMS are made of plastic materials and
may be used to treat patients with malignant obstruc-
tion or external compression of the upper gastrointes-
tinal tract, malignant gastrointestinal perforations, and
selected cases of benign upper gastrointestinal disease.
However, the effectiveness of SEMS placement for
gastric carcinomatous stenosis with diffuse extensive
cancer cell infiltration is unclear because there have been
few reports of such cases. A case in which SEMS place-
ment followed by second-line chemotherapy ameliorated
gastric carcinomatous stenosis, gave comparatively long-
term relief, and improved QOL is described here. The
usefulness, safety, and problems of this treatment are
discussed.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Contrast radiography of our patient on their initial
visit. Scirrhous type gastric cancer was distributed in the wide area
of the stomach with stricture of the gastric body seen on contrast
radiography.
Figure 2 Contrast radiography after the fourth cycle of first-line
chemotherapy. Contrast radiography revealed two sections of
stenosis in the esophago-gastric junction and gastric body. The
length of the stenosis from the gastric lower body to the antrum
was 4cm, and the pyloric ring was intact.
Kumagai et al. Journal of Medical Case Reports 2012, 6:315 Page 2 of 5
http://www.jmedicalcasereports.com/content/6/1/315Case presentation
A 74-year-old Japanese woman visited her local clinic
complaining of tarry stool one month prior to visiting
our department. She was referred to our department for
further examination. Contrast radiography and endoscopy
of the upper gastrointestinal tract revealed a scirrhous
type gastric cancer located in a wide area of the stomach
infiltrating the esophagogastric junction (EGJ), gastric
body, and antrum, with partial ulceration (Figure 1).
Biopsy specimens obtained from that lesion showed a
poorly-differentiated adenocarcinoma with signet-ring
cells. Immunohistochemically, the adenocarcinoma cells
were negative for human epidermal growth factor recep-
tor 2 (HER2; score 0). At this point, passage of contrast
agent through the stomach was possible. Whole body
computed tomography (CT) scans revealed multiple
metastases to the abdominal lymph nodes, liver, and
peritoneum. A moderate amount of malignant ascites
were also found. She had no relevant personal or family
history. Her laboratory data showed no major organ dys-
function except for a slight microcytic hypochromic
anemia. Her serum levels of carcinoembryonic antigen
(CEA) were within normal limits, but carbohydrate anti-
gen (CA) 19-9 levels were elevated to 50.0U/mL (normal
range of CA19-9: 0.0 to 37.0U/mL). Her Eastern Co-
operative Oncology Group (ECOG) performance status
(PS) was 1. PS1 is defined as restricted in physically
strenuous activity but ambulatory and able to carry out
work of a light or sedentary nature. Since curative sur-
gery was thought impossible, our patient was treated withsystemic chemotherapy consisting of cisplatin and S-1, an
oral dihydropyrimidine dehydrogenase (DPD)-inhibiting
fluoropyrimidine; 60mg/m2 of cisplatin was infused over
a two-hour period on day one, and 120mg/body/day of
S-1 was orally administered on days one to 14 every
three weeks. Two months after the initial course of
chemotherapy, disappearance of the metastatic liver
tumors and improvement of the malignant ascites were
observed. Her serum CA19-9 levels had also decreased
to within normal ranges. However, gradual appetite loss
had appeared during the fourth cycle in March 2011.
Upper gastrointestinal endoscopic examination revealed
two sections of stenosis in the EGJ and gastric body,
showing progression of disease. A large amount of un-
digested food residue remained, resulting in a gastric
outlet obstruction scoring system (GOOSS) score of 1
(score 0: no oral intake; score 1: liquids only; score 2:
soft foods; score 3: solid foods/full diet) [1]. Contrast
radiography revealed that the length of the stenosis
from the gastric lower body to the antrum was 4cm,
and, fortunately, the pyloric ring was intact (Figure 2).
CT scans showed that the metastatic lesions had not
deteriorated, but PS2 is defined as ambulatory and cap-
able of all selfcare but unable to carry out any work ac-
tivities. Up and about more than 50% of waking hours,
and the ascites increased. Gastro-jejunal bypass surgery
was not thought possible due to infiltration of carcin-
omatous cells across a wide area of the stomach. It was
finally decided to perform SEMS placement to achieve
Figure 4 Endoscopic image of the self-expandable metal stent.
Stent placement at the stenotic lesion of the gastric body was
successfully performed.
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limited stenosis involving the esophago-gastric junc-
tion and gastric antrum, life expectancy of more than
several months, and our patient’s wishes.
SEMS placement was performed targeting the gastric
antral stenosis on April 2011 using the OlympusW Model
GIF-XP260 and GIF-XQ240 (Olympus, Tokyo, Japan).
After balloon dilatation of the stenotic area, the delivery
catheter was inserted from the oral side of the stenosis
along a pre-placed guide wire, and then the SEMS
(6cm × 22mm, WallFlexW Duodenal Stent, Boston Scien-
tific, Boston, MA, USA) was placed under radiographic
guidance (Figure 3). A small amount of bleeding from the
carcinomatous mucosa and edematous change of the EGJ
from friction with the endoscope occurred (Figure 4). No
severe adverse events were observed during the SEMS
placement procedures. For seven days after SEMS place-
ment, our patient’s performance status and nutritional
condition deteriorated because of worsening of dysphagia
induced by the edematous change of the EGJ (GOOSS
score 0). Along with disappearance of the edema eight
days after SEMS placement, the dysphagia improved
enough to allow oral ingestion. Eight days after SEMS
placement, 80mg/m2 of paclitaxel (PTX) could be safely
administered as second-line chemotherapy (SLC). PTX
was administered on days one, eight, and 15 every four
weeks. Oral ingestion and nutritional status were restored
(GOOSS score 3, PS1) after starting SLC. These condi-
tions were maintained for 117 days until EGJ obstruction
occurred due to disease progression. The major adverseFigure 3 Contrast radiography on the day after stent
placement. The self-expandable metal stent was fully expanded and
the carcinomatous stricture of the gastric body was released, as seen
on contrast radiography.events of the chemotherapy were only mild general fa-
tigue (Common Terminology Criteria for Adverse Events
[CTCAE] version 4.0 grade 1) and minimal lasting periph-
eral neuropathy (grade 1). Our patient died of cancerous
cachexia resulting from disease progression 176 days after
SEMS placement and initiation of SLC.
Discussion
Our patient’s case showed progression of stenosis of the
gastric body and antrum along with disease progression
during first-line chemotherapy. Prompt amelioration of
symptoms and improvement of her general condition
were needed because our patient had developed weight
loss and poor nutritional status due to inadequate oral
uptake. There are several therapeutic options to facilitate
oral uptake for patients with stenosis of the upper
gastrointestinal tract, including chemotherapy, bypass
surgery, and stent placement [5,6]. Insertion of a naso-
gastric tube and gastrostomy enable only symptom relief
by reducing pressure in the gastrointestinal tract [2,3].
Although it has been estimated that SLC induces tumor
response in 20% of cases, it might not permit immediate
symptom relief [7-9]. In our patient’s case, bypass sur-
gery was not possible because the infiltrating carcin-
omatous cells were distributed across a wide area of the
stomach. We then considered stent placement in the
upper gastrointestinal tract. A previous report pro-
posed the indications and contraindications of SEMS
for gastrointestinal tract stenosis [4]. The indications
were inoperable malignant gastro-duodenal outlet ob-
struction, extrinsic compression by neoplastic or nodal
disease, anastomotic tumor recurrence after surgery,
malignant fistula to adjacent organs, benign strictures
refractory to balloon dilatation, and patients not being
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able disease by multimodality treatment, uncorrectable
coagulopathy, terminally ill patients with limited life
expectancy, peritoneal carcinomatosis with distal small
bowel obstruction, free gastrointestinal perforation, bowel
ischemia, and sepsis. However, favorable sites for stenoses
in the upper gastrointestinal tract for SEMS were not
well defined, and there have been few reports of SEMS
placement for wide stenotic lesions of the gastric body
and antrum because SEMS had not been thought suitable
for such cases [10,11]. Our patient had stenosis of the
gastric body and antrum, and SEMS placement was
thought appropriate because the length of the stenotic
region was 8 to 10cm (a length for which the device
might be suitable), the pyloric ring was intact, and some
space on the oral side of the stenotic region was available.
Finally, stent placement was successfully performed, oral
uptake recovered immediately, and our patient’s nutri-
tional status also improved. Stent placement in the upper
gastrointestinal tract could be appropriate even for
patients with poor performance status and multiple com-
plications because it is less invasive, has a good success
rate, and provides rapid symptom relief. Meanwhile,
adverse events, including bleeding in less than 1%, pain
in 2.5%, perforation in <1%, biliary obstruction in 1.3%,
and tumor ingrowth of the stent in 17% to 50%, have
been reported [4]. Stent migration also occurred in 0% to
5% with a bare-metal stent (BMS) and in 21% to 26%
with a covered stent [4]. Since various complications
induced by stent placement often occur in the thoracic
upper esophagus within 2cm of the esophageal entrance,
esophago-gastric junction, pylorus ring, and ampulla of
Vater, the location of stent placement requires careful
consideration. Although our patient had stenosis of both
the gastric body and the EGJ, with disease progression
during first-line chemotherapy, stent placement was
used only for the gastric body stenosis, not for the
EGJ stenosis. The stenosis of the EGJ was mild and an
endoscope could easily pass through the EGJ at that time.
In addition, the longest length of WallFlexW Duodenal
Stent does not have enough length to cover the distance
from the lower esophagus to pre-pylorus. Moreover, stent
placement at the EGJ was associated with a risk of stent
migration or persistent pain, vomiting and esophagitis
due to gastroesophageal reflux, because of expansion of
a physically narrowing region. As mentioned above, com-
plications related to stent placement in the EGJ, includ-
ing dropout of the stent, gastroesophageal reflux, and
aspiration pneumonia, have often been reported [12,13].
Recently, an anti-reflux stent that is expected to prevent
such complications, has been developed, and its practical
effectiveness has been verified [14].
In our patient’s case, stent placement in the gastric
body was an effective and durable treatment for thestenosis. Stent placement for stenosis of the esophagus
and duodenum has been well documented, but few
reports of stenting for gastric body stenosis were found.
This might be because carcinomatous stenosis tends to
appear in a wide area of the stomach involved with
scirrhous type carcinomas. Severe stenosis localized to
the gastric body or antrum could be a candidate for
this intervention. Selecting appropriate cases and technical
improvements could provide greater clinical benefit.
Since the survival benefit of SLC for metastatic gastric
carcinoma (MGC) has been proven, it is often considered
after failure of the prior chemotherapy [7,8,15]. In recent
years, a phase III study showed that SLC with CPT-11
(Camptothecin-11 or Irinotecan) or docetaxel for MGC
significantly improved overall survival (OS) compared
with best supportive care (BSC) alone (5.1 months for
SLC versus 3.8 months for BSC) [15]. SLC with weekly
paclitaxel has also been used based on a 16% to 24%
tumor response, and overall survival ranged from 3.5 to
8.0 months in several phase II studies [7,8]. In addition,
the toxicity of the weekly paclitaxel regimen was gener-
ally feasible for patients with MGC, even with moderate
carcinomatous ascites [8]. A phase III study comparing
bi-weekly CPT-11 (Camptothecin-11 or Irinotecan) and
weekly paclitaxel as SLC for MGC has also been con-
ducted in Japan. In our patient’s case, SLC with paclitaxel
was safely performed, and it inhibited stenosis of the
cardia and re-stenosis of the gastric body and antrum
after stent placement, so that long-term oral uptake
was achieved. Survival was longer than that reported in
the previous report [15]. No mechanical and symptom-
atic problems were found related to the stent placed in
the gastric body and antrum. Severe stenosis of the
gastrointestinal tract and fistula formation were often
observed in patients with advanced gastrointestinal
cancer. These diseases decrease oral uptake and perform-
ance status and induce infections such as pneumonia and
abscesses. In these cases, it is often difficult to administer
anti-cancer agents because of the patients’ poor general
condition or the risk of exacerbating infections. However,
immediate interventions, such as bypass surgery and
stent placement, might make it possible not only to
ameliorate symptoms, but also to provide a chance for
systemic chemotherapy, resulting in comparative pro-
longation of survival.
Conclusions
SEMS placement for carcinomatous stenosis in the
gastric body and antrum could be an effective thera-
peutic strategy for patients in poor general condition
in whom bypass surgery is not appropriate. This ap-
proach may provide rapid improvement of symptoms,
oral ingestion, prolong survival, and allow adequate
systemic chemotherapy.
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